<div style="margin: 12px 0px; font-family: arial; color: #333333; background: #ffffff; border: solid 4px #e5e5e5; width: 100%; clear: left;"><div class="CM_CTB_Content_Wrap" style="margin: 0px; padding: 0px;background-color: #ffffff;"><div style="border-bottom: solid 1px #dcdcdc; white-space: nowrap; margin-bottom: 8px; background-color: #eeeeee ;background-image: url(http://clipmarks.com/images/source-bg.gif); background-repeat: repeat-x; height: 24px; line-height: 24px; vertical-align: middle; padding-bottom: 4px; color: #666666; font-size: 10px;" ><a href="http://clipmarks.com/clip-to-blog/" title="see clips that are hot right now"><img src="http://content.clipmarks.com/blog_embed/0267a281-8f2d-4fff-8bb7-c5d2dc6adb19/79024897-6879-48E9-967E-660F7432B059/" alt="" width="19" height="19" border="0" style="vertical-align: middle; margin: 0px 4px; display: inline; border: none; float:none;" /></a>clipped from <a title="http://blogs.wsj.com/health/" href="http://blogs.wsj.com/health/" style="font-size: 11px;">blogs.wsj.com</a></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://blogs.wsj.com/health/"><P><IMG height="62" hspace="0" src="http://online.wsj.com/media/Lilly_blog_20070323084135.jpg" width="100" align="left" vspace="0" />Way back in the ’90s, Eli Lilly was going around saying its osteoporosis drug Evista reduced the risk of breast cancer and cardiovascular problems, even though the drug hadn’t been approved for those uses. The company got in trouble for that (<A href="http://online.wsj.com/article/SB113517500333728476.html" target="blank">$36 million fine</A>, guilty misdemeanor plea), but it turns out Lilly was half right. </P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://blogs.wsj.com/health/"><P>The FDA has given the company the go-ahead to promote the drug to reduce the risk of breast cancer in some women, Lilly <A href="http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=264036" target="blank">said</A> today. As part of the deal, though, the company also had to add a black-box warning to the<A href="http://pi.lilly.com/us/evista-pi.pdf" target="blank"> drug’s label</A>, calling out its possible increased risk of blood clots in the veins and fatal strokes in certain women. </P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://blogs.wsj.com/health/"></blockquote></div><div style="margin: 0px 6px 6px 4px;"><table style="font-size: 11px;border-spacing: 0px;padding: 0px;" cellpadding="0" cellspacing="0" width="100%"><tr><td style="background:transparent;border-width:0px;padding:0px;">&nbsp;</td><td align="right" style="background:transparent;border-width:0px;padding:0px;width:107px" width="107"><a href="http://clipmarks.com/share/79024897-6879-48E9-967E-660F7432B059/blog/" title="blog or email this clip"><img src="http://content6.clipmarks.com/images/c2b-foot.png" border="0" alt="blog it" width="107" height="17" style="border-width:0px;padding:0px;margin:0px;" /></a></td></tr></table></div></div>

New from the makers of Clipmarks:  Amplify.com - Don't just share the news...Amplify it!